Based on these results, two phase 3 trials are being planned for platinum -
sensitive and platinum - resistant
ovarian cancer patients by one of NCI's new National Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group
cancer patients by one of NCI's new National
Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group
Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG).
Recent studies have shown that rucaparib, a PARP inhibitor, effectively treats
patients with platinum -
sensitive, relapsed, high - grade
ovarian cancer harboring a BRCA mutation.
I ask my
patients about contraindications including blood clots, pregnancy, moderate to severe endometriosis, enlarging fibroids or associated with heavy bleeding, gallbladder disease, liver disease (because the liver processes estrogen and sends it to the gut via bile), unexplained vaginal bleeding, atypical hyperplasia of the breast, some types of estrogen -
sensitive breast
cancer, endometrial
cancer,
ovarian cancer.